Auris Medical to Report Second Half and Full Year 2020 Financial Results and Provide Business Update on Wednesday, March 31, 2021
Auris Medical Holding Ltd. (NASDAQ: EARS) will provide a business update and report financial results for the second half and full year 2020 on March 31, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Auris Medical Holding Ltd. (NASDAQ: EARS) will provide a business update and report financial results for the second half and full year 2020 on March 31, 2021. Following the announcement, management will host a conference call at 8:00 am ET. The company is focused on therapeutics for unmet medical needs in neurotology and CNS disorders. Key developments include AM-125 for vertigo in Phase 2, AM-201 in post Phase 1b, and two Phase 3 programs: Sonsuvi® for acute inner ear hearing loss and Keyzilen® for tinnitus.
Details
News Market Reaction – EARS
The recorded move for EARS in the trading session of this news was -3.87%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Hamilton, Bermuda, March 24, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that it will provide a business update and report its financial results for the second half and full year 2020 on Wednesday, March 31, 2021. Following the announcement, Auris Medical's management team will host a live conference call and webcast at 8:00 am Eastern Time (2:00 pm Central European Time).
To participate in this conference call, dial +1-877-870-9135 (US, toll free) or +44-2071-928-338 (international), and enter passcode 5649276. A live webcast of the conference call can be accessed in the Investor Relations section of the Auris Medical website at www.aurismedical.com. A replay will be available approximately two hours following the live call.
About Auris Medical
Auris Medical is a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders. The Company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125, in Phase 2) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201, post Phase 1b). Through its affiliate Altamira Medica, the Company is developing a nasal spray for protection against airborne viruses and allergens (AM-301). In addition, Auris Medical has two Phase 3 programs under development: Sonsuvi® (AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus. The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Auris Medical Holding Ltd. trade on the NASDAQ Capital Market under the symbol “EARS.”
Investor contact:
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.